Citadel Advisors’s Pacific Biosciences PACB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $2.08M | Sell |
1,576,051
-1,590,190
| -50% | -$2.84M | ﹤0.01% | 5984 |
|
|
2025
Q4 | $5.92M | Buy |
3,166,241
+667,887
| +27% | +$1.28M | ﹤0.01% | 4026 |
|
|
2025
Q3 | $3.2M | Buy |
+2,498,354
| New | +$3.38M | ﹤0.01% | 5191 |
|
|
2025
Q2 | – | Sell |
-22
| Closed | -$25 | – | 14378 |
|
|
2025
Q1 | $26 | Sell |
22
-360,959
| -100% | -$554K | ﹤0.01% | 14354 |
|
|
2024
Q4 | $661K | Buy |
360,981
+360,959
| +1,640,723% | +$705K | ﹤0.01% | 7945 |
|
|
2024
Q3 | $37 | Sell |
22
-904,179
| -100% | -$1.49M | ﹤0.01% | 14108 |
|
|
2024
Q2 | $1.24M | Sell |
904,201
-578,114
| -39% | -$1.17M | ﹤0.01% | 6183 |
|
|
2024
Q1 | $5.56M | Buy |
1,482,315
+937,811
| +172% | +$5.49M | ﹤0.01% | 3787 |
|
|
2023
Q4 | $5.34M | Sell |
544,504
-2,600,173
| -83% | -$21.3M | ﹤0.01% | 3685 |
|
|
2023
Q3 | $26.3M | Sell |
3,144,677
-776,626
| -20% | -$8.88M | 0.01% | 1608 |
|
|
2023
Q2 | $52.2M | Sell |
3,921,303
-1,127,669
| -22% | -$13.7M | 0.01% | 1012 |
|
|
2023
Q1 | $58.5M | Buy |
5,048,972
+472,312
| +10% | +$4.7M | 0.01% | 954 |
|
|
2022
Q4 | $37.4M | Sell |
4,576,660
-358,452
| -7% | -$3.09M | 0.01% | 1361 |
|
|
2022
Q3 | $28.6M | Buy |
4,935,112
+4,619,581
| +1,464% | +$26.5M | 0.01% | 1522 |
|
|
2022
Q2 | $1.4M | Sell |
315,531
-1,932,718
| -86% | -$11.7M | ﹤0.01% | 6279 |
|
|
2022
Q1 | $20.5M | Buy |
2,248,249
+1,893,895
| +534% | +$21.8M | ﹤0.01% | 1958 |
|
|
2021
Q4 | $7.25M | Sell |
354,354
-50,549
| -12% | -$1.22M | ﹤0.01% | 3647 |
|
|
2021
Q3 | $10.3M | Buy |
404,903
+138,246
| +52% | +$4.1M | ﹤0.01% | 3016 |
|
|
2021
Q2 | $9.32M | Sell |
266,657
-94,484
| -26% | -$2.75M | ﹤0.01% | 3190 |
|
|
2021
Q1 | $12M | Buy |
361,141
+329,583
| +1,044% | +$11.5M | ﹤0.01% | 2707 |
|
|
2020
Q4 | $819K | Sell |
31,558
-273,698
| -90% | -$4.65M | ﹤0.01% | 7210 |
|
|
2020
Q3 | $3.01M | Buy |
305,256
+133,603
| +78% | +$769K | ﹤0.01% | 3980 |
|
|
2020
Q2 | $592K | Buy |
171,653
+59,755
| +53% | +$203K | ﹤0.01% | 6768 |
|
|
2020
Q1 | $342K | Buy |
111,898
+80,548
| +257% | +$330K | ﹤0.01% | 7098 |
|
|
2019
Q4 | $161K | Buy |
31,350
+12,499
| +66% | +$63.5K | ﹤0.01% | 8323 |
|
|
2019
Q3 | $97K | Sell |
18,851
-4,398,454
| -100% | -$24.6M | ﹤0.01% | 8496 |
|
|
2019
Q2 | $26.7M | Buy |
4,417,305
+1,770,640
| +67% | +$12.4M | 0.01% | 1161 |
|
|
2019
Q1 | $19.1M | Buy |
2,646,665
+2,626,918
| +13,303% | +$19M | 0.01% | 1382 |
|
|
2018
Q4 | $146K | Sell |
19,747
-33,846
| -63% | -$214K | ﹤0.01% | 8074 |
|
|
2018
Q3 | $290K | Sell |
53,593
-597,075
| -92% | -$2.56M | ﹤0.01% | 7625 |
|
|
2018
Q2 | $2.31M | Buy |
650,668
+179,221
| +38% | +$497K | ﹤0.01% | 3892 |
|
|
2018
Q1 | $967K | Buy |
471,447
+352,475
| +296% | +$915K | ﹤0.01% | 4860 |
|
|
2017
Q4 | $314K | Buy |
118,972
+100,242
| +535% | +$351K | ﹤0.01% | 6386 |
|
|
2017
Q3 | $98K | Sell |
18,730
-33,291
| -64% | -$143K | ﹤0.01% | 7038 |
|
|
2017
Q2 | $185K | Sell |
52,021
-74,325
| -59% | -$300K | ﹤0.01% | 6617 |
|
|
2017
Q1 | $653K | Sell |
126,346
-9,687
| -7% | -$47.4K | ﹤0.01% | 4625 |
|
|
2016
Q4 | $517K | Sell |
136,033
-1,797,947
| -93% | -$13.1M | ﹤0.01% | 4844 |
|
|
2016
Q3 | $17.3M | Buy |
1,933,980
+1,423,093
| +279% | +$11.9M | 0.02% | 953 |
|
|
2016
Q2 | $3.59M | Buy |
510,887
+277,278
| +119% | +$2.53M | ﹤0.01% | 2126 |
|
|
2016
Q1 | $1.99M | Buy |
233,609
+33,973
| +17% | +$334K | ﹤0.01% | 2650 |
|
|
2015
Q4 | $2.62M | Buy |
199,636
+155,890
| +356% | +$1.4M | ﹤0.01% | 2472 |
|
|
2015
Q3 | $160K | Buy |
+43,746
| New | +$214K | ﹤0.01% | 6425 |
|
|
2015
Q1 | – | Sell |
-41,659
| Closed | -$327K | – | 8758 |
|
|
2014
Q4 | $327K | Buy |
41,659
+34,633
| +493% | +$222K | ﹤0.01% | 5308 |
|
|
2014
Q3 | $34K | Sell |
7,026
-37,654
| -84% | -$197K | ﹤0.01% | 7138 |
|
|
2014
Q2 | $276K | Buy |
+44,680
| New | +$224K | ﹤0.01% | 5164 |
|
|
2014
Q1 | – | Sell |
-24,884
| Closed | -$130K | – | 7969 |
|
|
2013
Q4 | $130K | Buy |
+24,884
| New | +$114K | ﹤0.01% | 5399 |
|
Other funds holding PACB
AIM
VCM
NAMA
Citadel Advisors's PACB Position: Q1 2026 in Review
Citadel Advisors reduced its Pacific Biosciences (PACB) stake by 50% in Q1 2026, selling an estimated $2.84M and leaving 1,576,051 shares worth $2.08M. The position accounts for ﹤0.01% of the portfolio, ranked #5984.
Citadel Advisors first reported a position in PACB in Q4 2013 and has held it in 46 quarters since. The position peaked at $58.5M in Q1 2023. 229 funds tracked by Wall St. Rank hold PACB as of Q1 2026.
- Citadel Advisors held 1,576,051 shares of Pacific Biosciences worth $2.08M as of Q1 2026.
- Citadel Advisors sold 1,590,190 Pacific Biosciences shares in Q1 2026, an estimated $2.84M.
- Pacific Biosciences made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #5984 holding.
- Citadel Advisors first reported a position in Pacific Biosciences in Q4 2013 and has held it in 46 quarters since.
- Citadel Advisors's Pacific Biosciences position peaked at $58.5M in Q1 2023.
- 229 funds tracked by Wall St. Rank held Pacific Biosciences as of Q1 2026.
Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.